Davis Polk advised AstraZeneca PLC in connection with its SEC-registered shelf takedown of $1 billion aggregate principal amount of 2.375% notes due 2022, $750 million aggregate principal amount of 3.125% notes due 2027 and $250 million aggregate principal amount of floating-rate notes due 2022. 

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines for three main therapy areas of healthcare: cardiovascular and metabolic diseases, oncology and respiratory.

The Davis Polk corporate team included partners John Banes and Leo Borchardt and associates Kate Darracott and Jason P. Thompson. Partner John D. Paton and associate Veronica Orecharova provided tax advice. Associate Preeti Krishnan provided 1940 Act advice. Members of the Davis Polk team are based in the London and New York offices.

Copy link to share post